Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

IMPower150: Implications for the Treatment of NSCLC

June 2nd 2018

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

June 2nd 2018

Actual Use of Pembrolizumab and Chemotherapy in NSCLC

June 2nd 2018

KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

June 2nd 2018

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma

June 2nd 2018

Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.

Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma

June 2nd 2018

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.